Physician profile
Michael C Corso
NPI 1194353250
$3,260.92
in general payments reported to CMS, 2019-2025
32 companies · $1,160 in 2025
The $1,160 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $25.34 · 2021: $141 · 2022: $209 · 2023: $660 · 2024: $1,065 · 2025: $1,160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,885.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,885.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $807.61 | 2021-2025 | Vraylar, Linzess, Viberzi |
| Novo Nordisk INC | $334.01 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $318.78 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $287.32 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $193.17 | 2021-2025 | |
| Corcept Therapeutics | $163.48 | 2024-2025 | Korlym |
| Abbott Laboratories | $117.50 | 2023-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals Lp | $105.38 | 2021-2025 | Airsupra, Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $83.94 | 2023-2025 | Xifaxan, Trulance |
| Sumitomo Pharma America, INC. | $78.92 | 2023-2025 | Gemtesa |
| Phathom Pharmaceuticals, INC. | $72.82 | 2024-2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $72.09 | 2024-2025 | |
| Axsome Therapeutics, INC. | $67.51 | 2024-2025 | Auvelity |
| Glaxosmithkline, LLC. | $64.72 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $61.06 | 2020-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $60.20 | 2023-2025 | Repatha, Otezla, Otezla |
| Xeris Pharmaceuticals, INC. | $51.95 | 2023-2025 | Gvoke Hypopen |
| Shield Therapeutics INC | $39.94 | 2024-2025 | |
| Dexcom, INC. | $36.42 | 2025 | Dexcom G6 Transmitter |
| Horizon Therapeutics Plc | $26.00 | 2023 | Krystexxa |
| Scilex Pharmaceuticals INC. | $24.39 | 2024 | |
| Daiichi Sankyo INC. | $22.53 | 2023 | Injectafer |
| Jazz Pharmaceuticals INC. | $22.11 | 2022 | |
| Leo Pharma INC. | $20.30 | 2023 | Adbry |
| Nestle Healthcare Nutrition INC. | $19.93 | 2023 | |
| Lundbeck LLC | $18.53 | 2024 | Rexulti |
| Exact Sciences Corporation | $16.07 | 2025 | Cologuard Collection Kit |
| Phadia US INC. | $15.93 | 2025 | Immunocap |
| Eisai INC. | $15.65 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $15.21 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.81 | 2025 | Caplyta |
| Ferring Pharmaceuticals INC. | $13.64 | 2023 | Euflexxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Corso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.